Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rhomboid domain containing 1 (RHBDD1) is an intramembrane serine protease located in the endoplasmic reticulum, where it participates in regulated intramembrane proteolysis of single- or multi-pass membrane proteins. It plays a role in the degradation of misfolded proteins via the ERAD pathway and modulates cell signaling, proteolytic processing, and apoptotic pathways. In cancer biology, RHBDD1 has been implicated as a potential oncogenic driver in colorectal cancer, enhancing tumor growth by promoting EGFR pathway activation via ADAM-independent cleavage and secretion of growth factors such as TGFα. While animal orthologs and related rhomboid proteases have diverse biological roles (including growth factor release in Drosophila), RHBDD1 specifically is associated in humans with protein quality control, apoptosis regulation, and cancer progression.
If a drug were to target RHBDD1, the likely mechanism would be inhibition of its serine protease activity, thereby reducing the cleavage of target membrane proteins, and consequently blocking activation of downstream pathways such as EGFR signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rhomboid domain containing 1 (RHBDD1).